Logo
T

TRexBio

51 employees

TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio is headquartered in South San Francisco, California.

Investor insights

Funding rounds participated in

$84M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2018

Funding rounds raised

Total raised

$84M

from 2 investors over 1 rounds

T

TRexBio raised $84M on December 13, 2024

Investors: Delos Capital and + 7 Other investors

FAQ